Therapy of infections due to carbapenem-resistant gram-negative pathogens

Chang Seop Lee, Yohei Doi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The prevalence of carbapenem-resistant gram-negative bacterial pathogens (CRGNs) has increased dramatically during the last 10 years, but the optimal treatment for CRGN infections is not well established due to the relative scarcity of robust clinical data. The polymyxins remain the most consistently active agents against CRGNs in vitro. Tigecycline, based on its in vitro antibacterial spectrum, could also be considered as a therapeutic option in the treatment of infections caused by certain CRGNs. Other agents, including aminoglycosides, rifampin, trimethoprim-sulfamethoxazole, fosfomycin and fluoroquinolones, could be considered as monotherapy or combination therapy against CRGNs in appropriate contexts, as combination therapy with two or more in vitro active drugs appears to be more effective than monotherapy based on some clinical data. Several promising new agents are in late-stage clinical development, including ceftolozane-tazobactam, ceftazidime-avibactam and plazomicin. Given the shortage of adequate treatment options, containment of CRGNs should be pursued through implementation of adequate infection prevention procedures and antimicrobial stewardship to reduce the disease burden and prevent future outbreaks of CRGNs.

Original languageEnglish
Pages (from-to)149-164
Number of pages16
JournalInfection and Chemotherapy
Volume46
Issue number3
DOIs
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Carbapenems
Infection
Therapeutics
Gram-Negative Bacterial Infections
Polymyxins
Fosfomycin
Fluoroquinolones
Sulfamethoxazole Drug Combination Trimethoprim
Aminoglycosides
Rifampin
Disease Outbreaks
Pharmaceutical Preparations
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{bdde22a328b546b68fe08b0a207cda9e,
title = "Therapy of infections due to carbapenem-resistant gram-negative pathogens",
abstract = "The prevalence of carbapenem-resistant gram-negative bacterial pathogens (CRGNs) has increased dramatically during the last 10 years, but the optimal treatment for CRGN infections is not well established due to the relative scarcity of robust clinical data. The polymyxins remain the most consistently active agents against CRGNs in vitro. Tigecycline, based on its in vitro antibacterial spectrum, could also be considered as a therapeutic option in the treatment of infections caused by certain CRGNs. Other agents, including aminoglycosides, rifampin, trimethoprim-sulfamethoxazole, fosfomycin and fluoroquinolones, could be considered as monotherapy or combination therapy against CRGNs in appropriate contexts, as combination therapy with two or more in vitro active drugs appears to be more effective than monotherapy based on some clinical data. Several promising new agents are in late-stage clinical development, including ceftolozane-tazobactam, ceftazidime-avibactam and plazomicin. Given the shortage of adequate treatment options, containment of CRGNs should be pursued through implementation of adequate infection prevention procedures and antimicrobial stewardship to reduce the disease burden and prevent future outbreaks of CRGNs.",
author = "Lee, {Chang Seop} and Yohei Doi",
year = "2014",
month = "1",
day = "1",
doi = "10.3947/ic.2014.46.3.149",
language = "English",
volume = "46",
pages = "149--164",
journal = "Infection and Chemotherapy",
issn = "2093-2340",
publisher = "Taehan Kamyom Hakhoe, Taehan Hwahak Yopop Hakhoe",
number = "3",

}

Therapy of infections due to carbapenem-resistant gram-negative pathogens. / Lee, Chang Seop; Doi, Yohei.

In: Infection and Chemotherapy, Vol. 46, No. 3, 01.01.2014, p. 149-164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapy of infections due to carbapenem-resistant gram-negative pathogens

AU - Lee, Chang Seop

AU - Doi, Yohei

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The prevalence of carbapenem-resistant gram-negative bacterial pathogens (CRGNs) has increased dramatically during the last 10 years, but the optimal treatment for CRGN infections is not well established due to the relative scarcity of robust clinical data. The polymyxins remain the most consistently active agents against CRGNs in vitro. Tigecycline, based on its in vitro antibacterial spectrum, could also be considered as a therapeutic option in the treatment of infections caused by certain CRGNs. Other agents, including aminoglycosides, rifampin, trimethoprim-sulfamethoxazole, fosfomycin and fluoroquinolones, could be considered as monotherapy or combination therapy against CRGNs in appropriate contexts, as combination therapy with two or more in vitro active drugs appears to be more effective than monotherapy based on some clinical data. Several promising new agents are in late-stage clinical development, including ceftolozane-tazobactam, ceftazidime-avibactam and plazomicin. Given the shortage of adequate treatment options, containment of CRGNs should be pursued through implementation of adequate infection prevention procedures and antimicrobial stewardship to reduce the disease burden and prevent future outbreaks of CRGNs.

AB - The prevalence of carbapenem-resistant gram-negative bacterial pathogens (CRGNs) has increased dramatically during the last 10 years, but the optimal treatment for CRGN infections is not well established due to the relative scarcity of robust clinical data. The polymyxins remain the most consistently active agents against CRGNs in vitro. Tigecycline, based on its in vitro antibacterial spectrum, could also be considered as a therapeutic option in the treatment of infections caused by certain CRGNs. Other agents, including aminoglycosides, rifampin, trimethoprim-sulfamethoxazole, fosfomycin and fluoroquinolones, could be considered as monotherapy or combination therapy against CRGNs in appropriate contexts, as combination therapy with two or more in vitro active drugs appears to be more effective than monotherapy based on some clinical data. Several promising new agents are in late-stage clinical development, including ceftolozane-tazobactam, ceftazidime-avibactam and plazomicin. Given the shortage of adequate treatment options, containment of CRGNs should be pursued through implementation of adequate infection prevention procedures and antimicrobial stewardship to reduce the disease burden and prevent future outbreaks of CRGNs.

UR - http://www.scopus.com/inward/record.url?scp=84908025463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908025463&partnerID=8YFLogxK

U2 - 10.3947/ic.2014.46.3.149

DO - 10.3947/ic.2014.46.3.149

M3 - Article

VL - 46

SP - 149

EP - 164

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

SN - 2093-2340

IS - 3

ER -